Search - tctmd.com

Displaying 21 - 32 of 32

Sort: Relevancy | Date

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2017

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Michael O'Riordan

November 21, 2017

Presentation AHA 2017

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Presenter: Steven Weisbord

November 13, 2017

News Conference News AHA 2017

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

Todd Neale

November 12, 2017

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shelley Wood

November 09, 2017

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

Shelley Wood

November 16, 2016

Presentation AHA 2016

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

Presenter: David M Kaye

November 15, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Conference News AHA 2012

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

Jason Kahn

November 04, 2012

Advertisement

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Novel Interatrial Shunt Succeeds in HF Hemodynamic Study: REDUCE LAP-HF I

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Interatrial Shunt Device Shows Sustained Improvement in Heart Failure Patients With Preserved EF

Transcatheter Intracardiac Shunt Device Provides Sustained Clinical Benefit at One Year in Heart Failure with Preserved or Mildly Reduced Ejection Fraction: The REDUCE LAP Heart Failure Trial

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content